Cargando…
Considerations for ensuring safety and efficacy of vaccines and therapeutic proteins manufactured by using platform approaches : summary of a workshop /
On September 15, 2008, the National Academies held the workshop "Considerations for Ensuring Safety and Efficacy of Vaccines and Therapeutic Proteins Manufactured by Using Platform Approaches". The workshop was planned and organized by an ad hoc planning committee made up of members of the...
| Clasificación: | Libro Electrónico |
|---|---|
| Autores Corporativos: | , |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Washington, D.C. :
National Academies Press,
©2010.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | EBSCO_ocn659579790 | ||
| 003 | OCoLC | ||
| 005 | 20231017213018.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 100830s2010 dcu o 000 0 eng d | ||
| 040 | |a N$T |b eng |e pn |c N$T |d YDXCP |d COF |d OCLCQ |d CNKEY |d E7B |d BUF |d IDEBK |d OCLCQ |d CSU |d OCLCQ |d OCLCF |d OCLCA |d OCLCQ |d OCLCO |d NLGGC |d MMU |d CDX |d OCLCO |d EBLCP |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d TOA |d AGLDB |d UAB |d MOR |d PIFAG |d OCLCQ |d ZCU |d OCLCQ |d MERUC |d OCLCQ |d MERER |d U3W |d OCLCO |d CUY |d OCLCQ |d STF |d WRM |d VNS |d OCLCQ |d VTS |d NRAMU |d OCLCQ |d ICG |d OCLCO |d VT2 |d AU@ |d OCLCQ |d OCLCO |d WYU |d LVT |d TKN |d OCLCQ |d DKC |d OCLCO |d OCLCQ |d M8D |d OCLCO |d OCLCQ |d OCLCO |d UKAHL |d OCLCQ |d K6U |d OCLCA |d OCLCO |d OCLCQ |d OCLCO | ||
| 019 | |a 642690239 |a 714046788 |a 740994757 |a 816565783 | ||
| 020 | |a 9780309153225 |q (electronic bk.) | ||
| 020 | |a 0309153220 |q (electronic bk.) | ||
| 020 | |a 1282660438 | ||
| 020 | |a 9781282660434 | ||
| 020 | |z 0309153212 |q (pbk.) | ||
| 020 | |z 9780309153218 |q (pbk.) | ||
| 029 | 1 | |a AU@ |b 000051320490 | |
| 029 | 1 | |a AU@ |b 000066750301 | |
| 029 | 1 | |a AU@ |b 000068806898 | |
| 029 | 1 | |a DEBBG |b BV043130511 | |
| 029 | 1 | |a DEBBG |b BV044109076 | |
| 029 | 1 | |a DEBSZ |b 421711507 | |
| 029 | 1 | |a NZ1 |b 14243184 | |
| 035 | |a (OCoLC)659579790 |z (OCoLC)642690239 |z (OCoLC)714046788 |z (OCoLC)740994757 |z (OCoLC)816565783 | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a UG447.8 |b .C66 2010eb | |
| 060 | 4 | |a 2010 L-470 | |
| 060 | 4 | |a WA 295 | |
| 072 | 7 | |a HIS |x 027010 |2 bisacsh | |
| 072 | 7 | |a M |2 bicssc | |
| 082 | 0 | 4 | |a 358.38 |2 22 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Considerations for ensuring safety and efficacy of vaccines and therapeutic proteins manufactured by using platform approaches : |b summary of a workshop / |c Jeffrey Fox, Marilee Shelton-Davenport, and India Hook-Barnard, rapporteurs ; Board on Life Sciences, Division on Earth and Life Studies, National Research Council of the National Academies. |
| 260 | |a Washington, D.C. : |b National Academies Press, |c ©2010. | ||
| 300 | |a 1 online resource (xi, 26 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 505 | 0 | |a Introduction -- TMTI case for versatile production platforms -- Discussion of TMTI efforts -- Platforms for large-scale monoclonal antibody production -- Presentation by Brian Kelley -- Presentation by Dane Zabriskie -- Discussion -- Suitability of platforms and supply needed -- Reducing timeline -- Manufacturing producation capacity -- Regulatory issues -- Platforms for vaccine production -- Presentation by Dave Robinson -- Discussion -- Various platforms -- Manufacturing facilities -- Regulatory issues -- Summary of key points. | |
| 520 | |a On September 15, 2008, the National Academies held the workshop "Considerations for Ensuring Safety and Efficacy of Vaccines and Therapeutic Proteins Manufactured by Using Platform Approaches". The workshop was planned and organized by an ad hoc planning committee made up of members of the Standing Committee on Biodefense at the US Department of Defense. The charge to the planning committee was to bring together scientists from academe, government, and the biotechnology industry to identify and discuss challenges and ideas related to the Transformational Medical Technologies Initiative's (TMTI) vision of developing countermeasures within a few months after a biologic-warfare agent is identified. The workshop focused on manufacturing processes and specifically on the development of "manufacturing platforms"--Repeatable components of manufacturing that reduce both development time and risk. An underlying assumption was that demonstrating that integrated platforms can reliably produce safe and efficacious countermeasures might shorten the regulatory approval process. Participants discussed manufacturing-related characteristics of monoclonal antibodies and vaccines. Although the planning committee understood that the TMTI efforts are broader than biologics and that TMTI platform approaches for biologics extend beyond monoclonal antibodies and vaccines, the planning committee believed that focusing on monoclonal antibodies and vaccines could illustrate some of the promise and challenges of platform approaches | ||
| 588 | 0 | |a Print version record. | |
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Biological warfare |z United States |x Safety measures. | |
| 650 | 0 | |a Monoclonal antibodies |x Therapeutic use. | |
| 650 | 0 | |a Drug approval |z United States. | |
| 650 | 0 | |a Vaccines |z United States. | |
| 650 | 0 | |a Vaccines. | |
| 650 | 1 | 2 | |a Biological Warfare |x prevention & control |
| 650 | 1 | 2 | |a Drug Approval |
| 650 | 2 | 2 | |a Antibodies, Monoclonal |x therapeutic use |
| 650 | 2 | 2 | |a Vaccines |
| 651 | 2 | |a United States | |
| 650 | 6 | |a Guerre biologique |z États-Unis |x Sécurité |x Mesures. | |
| 650 | 6 | |a Anticorps monoclonaux |x Emploi en thérapeutique. | |
| 650 | 6 | |a Médicaments |x Autorisation de mise sur le marché |z États-Unis. | |
| 650 | 6 | |a Vaccins |z États-Unis. | |
| 650 | 6 | |a Vaccins. | |
| 650 | 7 | |a HISTORY |x Military |x Biological & Chemical Warfare. |2 bisacsh | |
| 650 | 7 | |a Biological warfare |x Safety measures |2 fast | |
| 650 | 7 | |a Drug approval |2 fast | |
| 650 | 7 | |a Monoclonal antibodies |x Therapeutic use |2 fast | |
| 650 | 7 | |a Vaccines |2 fast | |
| 651 | 7 | |a United States |2 fast | |
| 700 | 1 | |a Fox, Jeffrey |q (Jeffrey L.) | |
| 700 | 1 | |a Shelton-Davenport, Marilee. | |
| 700 | 1 | |a Hook-Barnard, India. | |
| 710 | 2 | |a National Research Council (U.S.). |b Standing Committee on Biodefense at the U.S. Department of Defense. | |
| 710 | 2 | |a National Research Council (U.S.). |b Board on Life Sciences. | |
| 776 | 0 | 8 | |i Print version: |t Considerations for ensuring safety and efficacy of vaccines and therapeutic proteins manufactured by using platform approaches. |d Washington, D.C. : National Academies Press, ©2010 |z 9780309153218 |w (OCoLC)655759707 |
| 856 | 4 | 0 | |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=326079 |z Texto completo |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36559270 | ||
| 938 | |a Coutts Information Services |b COUT |n 14245619 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL3378635 | ||
| 938 | |a ebrary |b EBRY |n ebr10399497 | ||
| 938 | |a EBSCOhost |b EBSC |n 326079 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n 266043 | ||
| 938 | |a YBP Library Services |b YANK |n 3441527 | ||
| 994 | |a 92 |b IZTAP | ||